LW 347
Alternative Names: LW-347Latest Information Update: 11 Mar 2024
At a glance
- Originator Longwood Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 27 Feb 2024 LW 347 is available for licensing as of 27 Feb 2024. https://www.lwbpsh.com/en/research#collaboration
- 27 Feb 2024 Longwood Biopharma has patent protection for 'PD-1/PD-L1 small molecule inhibitor and preparation method and application thereof' worldwide
- 27 Feb 2024 Phase-I clinical trials in Solid tumours (PO) prior to February 2024 (Longwood Biopharma website, February 2024)